Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Generics UK

- PMLiVE

Change at the top at Teva as Vigodman departs

CEO replaced ad interim by chairman Yitzhak Peterburg as search begins

Sanofi reception

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

- PMLiVE

A healthy challenge

The EC’s Dr Vytenis Andriukaitis on Europe’s problems with health

Eli Lilly HQ

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients

EU flag

Pfizer’s first-in-class breast cancer therapy wins EU licence

Ibrance given the green light as a first-line treatment in Europe

- PMLiVE

Merck licenses University of Edinburgh research tool

Gains access to novel disease progression technology

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

- PMLiVE

Teva sells UK and Ireland assets to Intas Pharma for £603m

Generics portfolio and manufacturing facility gain set to double Indian firm’s UK sales

- PMLiVE

Pfizer decides against long-discussed break-up

Says dividing its R&D and generics businesses would disrupt rather than create value

- PMLiVE

Lundbeck trial failure dashes hopes in Alzheimer’s once again

Phase III trial fails to substantially improve cognition despite promising phase II data

EISAI

Eisai wins EU licence for kidney cancer drug Kisplyx

Approved as a second-line combination treatment for advanced RCC

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links